Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference
BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin Prices Public Offering of American Depositary Shares
BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced the pricing of the underwritten public offering of its American Depositary Shares ("ADSs") for gross proceeds of approximately $200.0 million , before deducting the
View HTML
Toggle Summary Amarin Announces Proposed Public Offering of American Depositary Shares
BEDMINSTER, N.J. and DUBLIN, Ireland , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced a registered underwritten public offering of its American Depositary Shares (“ADSs”).  All of the shares in the proposed offering are to be sold by Amarin.  The offering is
View HTML
Toggle Summary Amarin to Present at the Evercore ISI HealthCONx Conference
BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite E
Landmark Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular Outcomes Study of a Drug Intended to Address Residual Cardiovascular Risk Remaining After Cholesterol Management Cardiovascular Death Reduced by 20% Fatal or Nonfatal Heart Attacks
View HTML
Toggle Summary Amarin to Present at the Jefferies 2018 London Healthcare Conference
BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin Reports Third Quarter 2018 Financial Results and Provides Update on Operations
Activities Underway to Support Planned Commercial Expansion Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and
View HTML
Toggle Summary Amarin Schedules Webcast Discussion of Primary REDUCE-IT™ Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association
Webcast to Commence at 7:15 p.m. CT / 8:15 p.m. ET , Saturday, November 10, 2018 BEDMINSTER, N.J. and DUBLIN, Ireland , Oct. 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve
View HTML
Toggle Summary Amarin To Report Third Quarter 2018 Results and Host Conference Call On November 1, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members
View HTML
Toggle Summary Amarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in January 2017
BEDMINSTER, N.J. and DUBLIN, Ireland , Oct. 19, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), announced today that its wholly owned subsidiary, Corsicanto II Designated Activity Company, a designated activity company with limited liability incorporated under the laws
View HTML
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation